Search

Remi J Creusot

from New York, NY
Age ~49
Get Report
Connected to:
Carol A Creutz, 61Tim J CreutzKeith Crevatas, 41Martha J Creveling, 61Raymond H Creveling, 50Scott J Creveling, 69Chantal A Crevier, 31Gary J Crevier, 82Marc P Crevier, 73Dennis L Creviston, 48

Remi Creusot Phones & Addresses

  • New York, NY
  • San Francisco, CA
  • 195 Oak Grove Ave, Menlo Park, CA 94025
  • 137 Orchard Ave, Mountain View, CA 94043
  • Palo Alto, CA

Work

Company: Columbia university medical center Nov 2012 Position: Assistant professor

Education

School / High School: Stanford University School of Medicine 2003 to 2007 Specialities: Immunology

Skills

In Vivo • Molecular Imaging • Gene Expression • Immunology • Flow Cytometry • Animal Models • Cell Biology • Cell Culture • Facs • Molecular Biology • In Vitro • Tissue Culture • Elisa • Translational Research • Immunoassays • Diabetes • Dendritic Cells • T Cells • Autoimmunity • Immunotherapy • Molecular Cloning • Transfection • Pcr • Mouse Models • Inflammation • Translational Medicine • Gene Therapy • Immunofluorescence • Cell Signaling • Polymerase Chain Reaction

Languages

French • English

Industries

Research

Resumes

Resumes

Remi Creusot Photo 1

Assistant Professor

View page
Location:
New York, NY
Industry:
Research
Work:
Columbia University Medical Center
Assistant Professor
Stanford University Jun 2012 - Oct 2012
Instructor
Stanford University Aug 2007 - May 2012
Research Associate
Stanford University Jan 2003 - Jul 2007
Postdoctoral Fellow
University College London Mar 1999 - Dec 2002
Research Assistant and Grad Student
Education:
Stanford University School of Medicine 2003 - 2007
University of London 1999 - 2002
Doctorates, Doctor of Philosophy, Immunology Université Henri Poincaré, Nancy 1 1992 - 1998
Master of Science, Masters, Bachelors, Bachelor of Science, Biochemistry, Microbiology
Skills:
In Vivo
Molecular Imaging
Gene Expression
Immunology
Flow Cytometry
Animal Models
Cell Biology
Cell Culture
Facs
Molecular Biology
In Vitro
Tissue Culture
Elisa
Translational Research
Immunoassays
Diabetes
Dendritic Cells
T Cells
Autoimmunity
Immunotherapy
Molecular Cloning
Transfection
Pcr
Mouse Models
Inflammation
Translational Medicine
Gene Therapy
Immunofluorescence
Cell Signaling
Polymerase Chain Reaction
Languages:
French
English

Publications

Us Patents

Transient Expression Of Immunomodulatory Polypeptides For The Prevention And Treatment Of Autoimmune Disease, Allergy And Transplant Rejection

View page
US Patent:
8513208, Aug 20, 2013
Filed:
Feb 27, 2009
Appl. No.:
12/735932
Inventors:
Charles A. Nicolette - Durham NC, US
C. Garrison Fathman - Portola Valley CA, US
Remi Creusot - San Francisco CA, US
Assignee:
Argos Therapeutics, Inc. - Durham NC
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
C07H 21/02
C12Q 1/68
US Classification:
514 44, 536 231, 435 61
Abstract:
A method is provided for treating or preventing an undesired immune response in a patient, comprising: administering to said patient, cells that transiently express, and/or that are transfected with mRNA encoding, one or more polypeptides selected from the group consisting of an IL-4 receptor agonist, an IFN-γ receptor antagonist, an IFN-α receptor antagonist, an IL-12 receptor antagonist, an IL-23 receptor antagonist, and a TNF antagonist. Preferably, the cells selectively accumulate in one or more secondary lymphoid tissues at or proximate to the site of the undesired immune response. Related compositions are provided. The methods and compositions are useful for the treatment or prevention of undesired immune responses including, but not limited to, transplant rejection, autoimmune disease, allergy and immune responses directed against therapeutic compositions.

Enhanced Car Tregs And Bi-Specific Antibodies For Induction Of Immune Tolerance, Treating Autoimmune Diseases And Preventing Transplantation Rejection

View page
US Patent:
20210268023, Sep 2, 2021
Filed:
Mar 1, 2021
Appl. No.:
17/188640
Inventors:
- New York NY, US
Remi Creusot - New York NY, US
International Classification:
A61K 35/17
A61P 37/02
C07K 14/74
C07K 14/725
A61K 45/06
Abstract:
The present disclosure provides for conversion-resistant CAR regulatory T cells (Tregs) and bi-specific antibodies, and methods to use these Tregs and antibodies for the treatment of autoimmune diseases and for prevention of organ transplant rejection.

Nucleic Acid Constructs For Presentation Of Cd4 And Cd8 Epitopes, Cellular Transfection And Uses Thereof

View page
US Patent:
20170283810, Oct 5, 2017
Filed:
Apr 10, 2017
Appl. No.:
15/483889
Inventors:
Remi J. Creusot - New York NY, US
Assignee:
The Trustees of Columbia University in the City of New York - New York NY
International Classification:
C12N 15/63
A61K 39/42
C12Q 1/68
A61K 35/76
Abstract:
The invention relates to constructs, cells and methods for modulating the immune system that optimize presentation of CD4 and CD8 epitopes to antigen-presenting cells and transfection into cells. Epitopes to either self antigens or non-self antigens can be used to optimize either a tolerance or immunogenicity to those epitopes, respectively. Certain new constructs encode one or more dominant, disease-driving epitopes (CD4) targeted for MHCII processing within the endosomes of a cell and one or more epitopes (CD8) targeted for MHCI processing within the cytosol of the cell, to produce the maximum antigen/epitope presentation in the immune system, and further include an MHCII activator sequence. Alternatively, the new constructs encode CD4 and CD8 epitopes operably linked to a secretion signal.
Control profile
Remi J Creusot from New York, NY, age ~49 Get Report